Literature DB >> 25932443

Scoring system for detecting spurious hemolysis in anticoagulated blood specimens.

Gilsung Yoo1, Juwon Kim1, Young Uh1, Kwang Ro Yoon1, Soon Deok Park1, Kap Jun Yoon1.   

Abstract

BACKGROUND: The identification of in vitro hemolysis (IVH) using a hematology analyzer is challenging because centrifugation of the specimens cannot be performed for cell counts. In the present study, we aimed to develop a scoring system to help identify the presence of hemolysis in anticoagulated blood specimens.
METHODS: Thirty-seven potassium EDTA anticoagulated blood specimens were obtained, and each specimen was divided into 3 aliquots (A, B, and C). Aliquots B and C were mechanically hemolyzed by aspirating 2 and 5 times, respectively, using a 27-gauge needle and then tested; aliquot A was analyzed immediately without any hemolysis. After the cells were counted, aliquots B and C were centrifuged and the supernatants were tested for the hemolytic index and lactate dehydrogenase levels.
RESULTS: The 4 hematologic parameters were selected and scored from 0 to 3 as follows:< 34.0, 34.0-36.2, 36.3-38.4, and ≥38.5 for mean cell hemoglobin concentration (MCHC, g/dL); <0.02, 0.02, 0.03, and ≥0.04 for red blood cell ghosts (10(12)/L); <0.13, 0.13-0.38, 0.39-1.30, and ≥1.31 for difference value (g/dL) of measured hemoglobin and calculated hemoglobin; and <0.26, 0.26-0.95, 0.96-3.34, and ≥3.35 for difference value (g/dL) of MCHC and cell hemoglobin concentration mean. The hemolysis score was calculated by adding all the scores from the 4 parameters. At the cutoff hemolysis score of 3, the IVH of aliquots B and C were detected as 64.9% and 91.9%, respectively.
CONCLUSIONS: The scoring system might provide effective screening for detecting spurious IVH.

Entities:  

Keywords:  Analyzer; Anticoagulants; Hemolysis; Score; System

Mesh:

Substances:

Year:  2015        PMID: 25932443      PMCID: PMC4390703          DOI: 10.3343/alm.2015.35.3.341

Source DB:  PubMed          Journal:  Ann Lab Med        ISSN: 2234-3806            Impact factor:   3.464


INTRODUCTION

The presence of hemolysis, icterus, and lipemia (HIL) in clinical specimens is known to interfere with the accurate measurement of various analytes. The identification of clinical specimens with HIL is desirable when laboratories have the resources for reducing or eliminating some of these preanalytical interferents. The main method for detecting and reporting HIL interference has involved the inspection of individual specimens by laboratory personnel. At present, the development of sophisticated chemistry analyzers has enabled the automatic detection of HIL status and reporting of HIL index values [1, 2]. However, the identification of HIL in specimens for hematology analysis is challenging because centrifugation of the specimens cannot be performed for cell counts. It is important to detect in vitro hemolysis (IVH) because it is the most frequently encountered during HIL interference [3]. The presence of IVH in a specimen being examined with a hematology analyzer may result in a spurious increase in measured Hb (mHb) concentration and platelet (PLT) count and a spurious decrease in red blood cell (RBC) count, Hct, and mean cell volume (MCV) [4]. An abnormality in one of these measured parameters eventually leads to abnormal calculated RBC indices, such as mean cell hemoglobin (MCH) and mean cell hemoglobin concentration (MCHC) [4]. Therefore, laboratory applications of sensitive and reliable hematologic flags or indices for identifying clinically significant IVH might reduce laboratory turnaround time and recheck and/or recollection of specimens. In the present study, we aimed to investigate the hemolytic effects on various hematologic parameters to determine the hematologic parameters that are indicative of clinically significant IVH. Moreover, we developed a scoring system that is sensitive and effective for detecting IVH.

METHODS

1. Laboratory analyses

This prospective study was performed during the period of December 2012 by using 37 consecutive fresh human blood specimens that were anticoagulated with EDTA (BD Vacutainer K2 EDTA 5.4 mg, REF 367835, Becton Dickinson, Franklin Lakes, NJ, USA). All EDTA blood specimens were obtained during medical check-ups. Each specimen was divided into 3 aliquots. The first aliquot (A) was immediately tested, and the second and third aliquots (B and C, respectively) were tested after being mechanically hemolyzed by aspirating two and five times, respectively, using a 27-gauge needle. For all specimens, complete blood cell count (CBC) and automated differential count were obtained by the Advia 2120i (Siemens Healthcare Diagnostics, Sacramento, CA, USA) CBC/Diff mode. After the cells were counted, aliquots B and C were centrifuged and the supernatants were tested for hemolytic index (HI) and lactate dehydrogenase (LDH) levels using Modular DPE system (Roche Diagnostics, Bazel, Switzerland).

2. Statistical analyses

Data were analyzed by using IBM SPSS Statistics version 20 (SPSS Inc., Chicago, IL, USA). The [B-A] data set was obtained by subtracting the results of aliquot A from those of aliquot B, and the [C-A] data set was obtained by subtracting the results of aliquot A from those of aliquot C. Linear regression analysis was performed for the [B-A] and [C-A] data sets to define the correlation coefficients between objective hemolysis parameters (HI, LDH) and hematologic parameters, respectively. A paired t-test was performed to compare the mean difference of hematologic parameters between non-hemolyzed and hemolyzed specimens. A Kolmogorov-Smirnov test was performed to verify the assumption of normality. Procedures for selecting sensitive and reliable variables are described below. First, the higher correlation coefficients (P<0.05) between hematologic and objective hemolysis parameters (HI, LDH) were selected from both [B-A] and [C-A] data sets. Second, we selected hematologic parameters in which the data ranges between the hemolyzed and non-hemolyzed specimens did not overlap. Third, hematologic parameters with normality (P>0.05) and mean values that were statistically different between the [B-A] and [C-A] data sets (P<0.05) were selected.

RESULTS

The mean±SD values of the HI for aliquots B and C were 1,121±147 and 3,298±328, respectively. The mean±SD values of the LDH levels for aliquots B and C were 1,599±179 U/L and 4,292±517 U/L, respectively. The correlation coefficients (P<0.05) between the hematologic parameters and HI in [B-A] and [C-A] data sets, in order of decreasing absolute percent difference, were as follows: mHb-calculated hemoglobin (cHb) (r=0.751 and r=0.943, respectively), Hct (r=-0.768 and r=-0.912, respectively), MCH (r=0.735 and r=0.905, respectively), MCHC (r=0.787 and r=0.850, respectively), cHb (r=-0.730 and r=-0.847, respectively), RBC count (r=-0.777 and r=-0.846, respectively), MCHC-cell hemoglobin concentration mean (CHCM) (r=0.766 and r=0.842, respectively), reticulocyte number (RETIC-N; r=-0.633 and r=-0.367, respectively), and MCV (r=-0.573 and r=-0.415, respectively; Table 1).
Table 1

Correlation of objective hemolysis and hematologic parameters

Hematologic parameters (unit)Hemolytic index*Lactate dehydrogenase
[B-A][C-A]§[B-A][C-A]§
rPrPrPrP
WBC (109/L)-0.279NS-0.005NS-0.280NS-0.250NS
RBC (1012/L)-0.777< 0.001-0.846< 0.001-0.791< 0.001-0.655< 0.001
mHb (g/dL)-0.3370.041-0.074NS-0.3520.033-0.089NS
Hct (%)-0.768< 0.001-0.912< 0.001-0.791< 0.001-0.712< 0.001
MCV (fL)-0.573< 0.001-0.4150.012-0.585< 0.001-0.4150.012
MCH (pg)0.735< 0.0010.905< 0.0010.761< 0.0010.657< 0.001
MCHC (g/dL)0.787< 0.0010.850< 0.0010.803< 0.0010.635< 0.001
CHCM (g/dL)0.203NS0.099NS0.207NS0.136NS
CH (pg)0.014NS-0.258NS0.012NS-0.101NS
RDW (%)-0.082NS0.141NS-0.071NS0.005NS
HDW (g/dL)-0.098NS0.316NS-0.091NS0.091NS
PLT (109/L)0.073NS0.247NS0.071NS0.139NS
MPV (fL)-0.260NS0.133NS-0.255NS0.005NS
Hyper (%)0.226NS0.128NS0.246NS0.142NS
Hypo (%)0.057NS0.197NS0.043NS0.137NS
Macro (%)-0.3690.025-0.166NS-0.3950.016-0.134NS
Micro (%)-0.051NS0.257NS-0.045NS0.114NS
RBC Fragments (1012/L)-0.091NS0.212NS-0.089NS0.169NS
RBC Ghosts (1012/L)0.319NS0.606< 0.0010.3410.0390.4440.006
MN (%)-0.262NS-0.4450.006-0.252NS-0.4610.004
PMN (%)0.302NS0.4310.0080.293NS0.4780.003
CHb (g/dL)-0.730< 0.001-0.847< 0.001-0.747< 0.001-0.648< 0.001
NEUT (%)-0.111NS-0.040NS-0.104NS0.036NS
LYMPH (%)0.251NS0.021NS0.248NS0.020NS
MONO (%)-0.050NS-0.297NS-0.043NS-0.3530.032
EOS (%)-0.096NS0.278NS-0.110NS0.263NS
BASO (%)-0.147NS0.036NS-0.147NS-0.085NS
LUC (%)-0.128NS0.3250.050-0.132NS0.3590.029
LI0.049NS-0.212NS0.053NS-0.175NS
MPXI-0.210NS0.201NS-0.204NS0.061NS
WBCP (109/L)-0.4680.005-0.258NS-0.4800.004-0.596< 0.001
RETIC-P (%)-0.336NS-0.139NS-0.343NS-0.118NS
RETIC-N-0.633< 0.001-0.3670.039-0.634< 0.001-0.3500.049
CHr (pg)0.113NS-0.237NS0.107NS-0.235NS
CHm (pg)0.123NS-0.277NS0.122NS-0.269NS
mHb-cHb (g/dL)0.751< 0.0010.943< 0.0010.762< 0.0010.710< 0.001
MCHC-CHCM (g/dL)0.766< 0.0010.842< 0.0010.782< 0.0010.620< 0.001

*Mean±SD values in aliquots B and C were 1,121±147 and 3,298±328, respectively; †Mean±SD values in aliquots B and C were 1,599±179 U/L and 4,292±517 U/L, respectively; ‡[B-A] is defined as the data set obtained by subtracting the results of aliquot A from those of aliquot B; §[C-A] is defined as the data set obtained by subtracting the results of aliquot A from those of aliquot C.

Abbreviations: r, correlation coefficient; P, P value; WBC, white blood cell; NS, not significant; RBC, red blood cell; mHb, hemoglobin concentration measured by the colorimetric method; MCV, mean cell volume; MCH, mean cell hemoglobin; MCHC, mean cell hemoglobin concentration; CHCM, cell hemoglobin concentration mean; CH, cellular hemoglobin content (mean of RBC cellular hemoglobin histogram); RDW, red cell distribution width; HDW, hemoglobin distribution width; PLT, platelet; MPV, mean platelet volume; Hyper, hyperchromia; Hypo, hypochromia; Macro, macrocytosis; Micro, microcytosis; MN, mononuclear cell; PMN, polymorphonuclear cell; cHb, calculated hemoglobin (CHCM×RBC×MCV÷1,000); NEUT, neutrophil; LYMPH, lymphocyte; MONO, monocyte; EOS, eosinophil; BASO, basophil; LUC, large unstained cell; LI, lobularity index; MPXI, myeloperoxidase index; WBCP, white blood cell count by peroxidase; RETIC-P, reticulocyte percent; RETIC-N, reticulocyte number; CHr, cellular hemoglobin mean of reticulocyte; CHm, cellular hemoglobin mean of mature RBC; mHb-cHb, mHb minus cHb; MCHC-CHCM, MCHC minus CHCM.

The data ranges of MCHC, RBC ghosts, mHb-cHb, and MCHC-CHCM in hemolyzed specimens showed minimum overlap with those in non-hemolyzed specimens (Table 2).
Table 2

Data of hemolyzed and non-hemolyzed specimens by hematologic parameters

Hematologic parameters (unit)Data of hemolyzed and non-hemolyzed specimens
Aliquot AAliquot BAliquot C
Mean±SDRangeMean±SDRangeN (%) of overlap*Mean±SDRangeN (%) of overlap*
WBC (109/L)5.01 ± 1.382.86-9.674.84 ± 1.202.99-8.6837 (100)5.06 ± 1.273.00-9.0837 (100)
RBC (1012/L)4.82 ± 0.593.34-5.894.68 ± 0.622.90-5.9036 (97.3)4.12 ± 0.792.50-5.5628 (75.7)
mHb (g/dL)14.84 ± 1.5911.6-18.214.95 ± 1.6311.5-17.936 (97.3)14.71 ± 1.6211.7-17.837 (100)
Hct (%)44.18 ± 4.8033.4-53.141.89 ± 5.1428.3-51.636 (97.3)36.72 ± 6.7823.9-47.125 (67.6)
MCV (fL)91.84 ± 3.7884.2-99.889.88 ± 3.5483.3-96.436 (97.3)89.38 ± 3.3783.4-95.635 (94.6)
MCH (pg)30.86 ± 1.3028.4-34.632.13 ± 2.0629.2-38.933 (89.2)36.54 ± 5.1029.0-48.517 (45.9)
MCHC (g/dL)33.63 ± 0.6732.3-35.335.67 ± 1.5333.9-40.520 (54.1)40.30 ± 5.2934.6-57.27 (18.9)
33.4-33.935.2-36.238.5-42.1
CHCM (g/dL)34.08 ± 0.7632.6-35.735.15 ± 0.7533.9-36.626 (70.3)35.19 ± 0.7034.2-36.627 (73.0)
CH (pg)31.12 ± 1.1828.9-34.231.44 ± 1.2329.0-35.035 (94.6)31.30 ± 1.2328.9-34.836 (97.3)
RDW (%)12.61 ± 1.802.50-14.112.33 ± 1.732.60-13.737 (100)12.34 ± 1.712.70-13.937 (100)
HDW (g/dL)2.56 ± 0.202.24-3.022.54 ± 0.192.20-3.0735 (94.6)2.57 ± 0.182.30-3.1135 (94.6)
PLT (109/L)241.27 ± 43.07174-340225.49 ± 38.33158-31935 (94.6)236.49 ± 44.84169-34535 (94.6)
MPV (fL)8.28 ± 1.116.50-11.18.41 ± 0.766.90-10.037 (100)8.51 ± 0.687.20-10.037 (100)
Hyper (%)1.03 ± 0.650.30-3.101.90 ± 1.270.50-5.8032 (86.5)1.99 ± 1.270.60-6.3032 (86.5)
Hypo (%)0.61 ± 0.550.10-2.100.22 ± 0.150.10-0.6037 (100)0.24 ± 0.180.10-0.8037 (100)
Macro (%)1.18 ± 1.090.20-5.600.64 ± 0.640.10-2.9032 (86.5)0.54 ± 0.520.10-2.5032 (86.5)
Micro (%)0.37 ± 0.220.10-1.400.44 ± 0.250.10-1.4037 (100)0.48 ± 0.230.20-1.3037 (100)
RBC Fragments (1012/L)0.01 ± 0.000.01-0.020.01 ± 0.000.01-0.0237 (100)0.01 ± 0.000.01-0.0237 (100)
RBC Ghosts (1012/L)0.01 ± 0.000.00-0.020.02 ± 0.010.01-0.0434 (91.9)0.03 ± 0.010.01-0.0614 (37.8)
0.01-0.010.02-0.020.02-0.03
MN (%)38.44 ± 8.0817.1-51.936.01 ± 7.3916.7-48.036 (97.3)33.65 ± 7.9819.5-52.336 (97.3)
PMN (%)60.65 ± 7.8046.8-82.063.00 ± 7.3651.0-82.736 (97.3)64.64 ± 7.9446.5-79.536 (97.3)
cHb (g/dL)15.05 ± 1.7111.4-18.514.74 ± 1.8010.3-18.236 (97.3)12.91 ± 2.408.7-16.625 (67.6)
NEUT (%)55.00 ± 8.0741.3-73.156.18 ± 8.0742.8-75.335 (94.6)56.33 ± 8.1240.9-76.135 (94.6)
LYMPH (%)33.26 ± 8.1111.4-48.133.06 ± 7.5315.9-49.236 (97.3)32.65 ± 7.4514.9-46.137 (100)
MONO (%)5.32 ± 1.282.80-8.805.34 ± 1.324.00-9.0035 (94.6)5.51 ± 1.193.50-8.8037 (100)
EOS (%)2.70 ± 1.990.20-9.602.84 ± 1.910.50-8.6035 (94.6)2.67 ± 1.800.30-8.2037 (100)
BASO (%)0.65 ± 0.310.20-1.800.51 ± 0.190.20-1.0035 (94.6)0.64 ± 0.260.20-1.2037 (100)
LUC (%)2.22 ± 0.631.10-4.102.08 ± 0.651.10-3.4035 (94.6)2.20 ± 0.631.20-4.1037 (100)
LI2.16 ± 0.101.93-2.332.16 ± 0.101.81-2.3236 (97.3)2.13 ± 0.111.70-2.3136 (97.3)
MPXI-2.16 ± 3.18-8.0-4.0-3.58 ± 3.24-11.0-4.035 (94.6)-3.92 ± 2.90-12.0-1.335 (94.6)
WBCP (109/L)5.11 ± 1.452.80-10.34.85 ± 1.302.82-8.8135 (94.6)4.82 ± 1.212.82-8.5037 (100)
RETIC-P (%)1.64 ± 0.390.84-2.451.42 ± 0.330.75-2.5235 (94.6)1.40 ± 0.320.87-2.3236 (97.3)
RETIC-N79.75 ± 21.9944.2-131.667.04 ± 19.3039.0-130.232 (86.5)58.00 ± 19.7827.3-117.828 (75.7)
CHr (pg)32.09 ± 1.669.40-26.633.01 ± 1.2731.1-36.635 (94.6)32.80 ± 1.5528.0-36.936 (97.3)
CHm (pg)30.53 ± 1.2827.8-34.031.24 ± 1.1928.8-34.736 (97.3)31.14 ± 1.2329.0-34.036 (97.3)
mHb-cHb (g/dL)-0.21 ± 0.27-0.80-0.500.21 ± 0.51-0.60-1.7031 (83.8)1.79 ± 1.47-0.40-5.809 (24.3)
-0.30- -0.120.04-0.381.31-2.28
MCHC-CHCM (g/dL)-0.45 ± 0.59-1.40-1.600.51 ± 1.30-1.40-4.0032 (86.5)5.10 ± 5.27-1.00-21.914 (37.8)
-0.65- -0.250.08-0.953.35-6.86

*Overlap refers to the number (%) of samples lying within the range of the aliquot A group; †95% confidence interval.

Abbreviations: WBC, white blood cell; RBC, red blood cell; mHb, hemoglobin concentration measured by the colorimetric method; MCV, mean cell volume; MCH, mean cell hemoglobin; MCHC, mean cell hemoglobin concentration; CHCM, cell hemoglobin concentration mean; CH, cellular hemoglobin content (mean of RBC cellular hemoglobin histogram); RDW, red cell distribution width; HDW, hemoglobin distribution width; PLT, platelet; MPV, mean platelet volume; Hyper, hyperchromia; Hypo, hypochromia; Macro, macrocytosis; Micro, microcytosis; MN, mononuclear cell; PMN, polymorphonuclear cell; cHb, calculated hemoglobin (CHCM×RBC×MCV÷1,000); NEUT, neutrophil; LYMPH, lymphocyte; MONO, monocyte; EOS, eosinophil; BASO, basophil; LUC, large unstained cell; LI, lobularity index; MPXI, myeloperoxidase index; WBCP, white blood cell count by peroxidase; RETIC-P, reticulocyte percent; RETIC-N, reticulocyte number; CHr, cellular hemoglobin mean of reticulocyte; CHm, cellular hemoglobin mean of mature RBC.

The hematologic parameters with normality and mean values with a significant difference between the [B-A] and [C-A] data sets, in order of decreasing absolute percent difference, were as follows: mHb-cHb (300% and 952%, respectively), MCH (4.1% and 18.4%, respectively), Hct (-5.2% and -16.9%, respectively), RBC count (-2.9% and -14.5%, respectively), cHb (-2.1% and -14.2%, respectively), mononuclear cell percentage (MN%, -6.4% and -12.8%, respectively), polymorphonuclear cell percentage (PMN%, 3.8% and 6.6%, respectively), and white blood cell perox (WBCP) count (-3.5% and -5.7%, respectively; Table 3).
Table 3

Statistical data of hematologic parameters between hemolyzed and non-hemolyzed specimens

Hematologic parameters (unit)P value by Kolmogorov-Smirnov testComparison of mean by paired t-test
[B - A]*[C - A][B - A][C - A]
MeanSDPMeanSDP
WBC (109/L)0.1020.200-0.170.350.0060.050.230.185
RBC (1012/L)0.1750.200-0.140.19< 0.001-0.700.51< 0.001
mHb (g/dL)0.0510.0060.110.390.111-0.140.530.121
Hct (%)0.1290.200-2.292.04< 0.001-7.464.57< 0.001
MCV (fL)0.0630.016-1.910.70< 0.001-2.411.54< 0.001
MCH (pg)0.0810.1461.271.19< 0.0015.684.55< 0.001
MCHC (g/dL)0.0500.0372.041.33< 0.0016.675.24< 0.001
CHCM (g/dL)0.0010.0301.080.55< 0.0011.110.76< 0.001
CH (pg)< 0.001< 0.0010.320.530.0010.180.490.028
RDW (%)0.0010.001-0.290.43< 0.001-0.270.460.001
HDW (g/dL)< 0.0010.032-0.010.120.4480.010.160.761
PLT (109/L)0.2000.146-15.7813.32< 0.001-4.7822.990.214
MPV (fL)< 0.0010.0080.120.880.3960.230.990.172
Hyper (%)< 0.001< 0.0010.870.82< 0.0010.961.08< 0.001
Hypo (%)0.001< 0.001-0.390.50< 0.001-0.380.52< 0.001
Macro (%)0.0320.139-0.540.52< 0.001-0.640.62< 0.001
Micro (%)< 0.0010.0010.080.10< 0.0010.110.11< 0.001
RBC Fragments (1012/L)< 0.001< 0.0010.000.000.0030.000.000.017
RBC Ghosts (1012/L)< 0.0010.0090.010.01< 0.0010.020.01< 0.001
MN (%)0.2000.200-2.442.27< 0.001-4.795.24< 0.001
PMN (%)0.2000.2002.302.18< 0.0013.985.24< 0.001
cHb (g/dL)0.2000.200-0.320.680.007-2.141.70< 0.001
NEUT (%)0.2000.0020.881.620.0031.343.160.014
LYMPH (%)0.1280.006-0.761.570.007-0.616.320.560
MONO (%)0.2000.2000.050.730.6620.190.730.114
EOS (%)0.0040.0060.060.650.604-0.020.590.802
BASO (%)0.0400.031-0.130.320.022-0.020.360.786
LUC (%)0.0870.200-0.100.470.202-0.020.540.856
LI0.2000.200-0.010.120.737-0.030.160.204
MPXI< 0.0010.023-1.261.63< 0.001-1.752.07< 0.001
WBCP (109/L)0.2000.143-0.180.360.007-0.290.35< 0.001
RETIC-P (%)0.2000.043-0.240.17< 0.001-0.220.350.001
RETIC-N0.2000.062-13.78.79< 0.001-19.4022.55< 0.001
CHr (pg)< 0.001< 0.0010.721.070.0010.591.070.004
CHm (pg)< 0.001< 0.0010.661.060.0010.491.040.012
mHb-cHb (g/dL)0.1660.0870.420.49< 0.0012.011.48< 0.001
MCHC-CHCM (g/dL)0.0770.0460.961.22< 0.0015.555.20< 0.001

*[B-A] is defined as the data set obtained by subtracting the results of aliquot A from those of aliquot B; †[C-A] is defined as the data set obtained by subtracting the results of aliquot A from those of aliquot C.

Abbreviations: WBC, white blood cell; RBC, red blood cell; mHb, hemoglobin concentration measured by the colorimetric method; MCV, mean cell volume; MCH, mean cell hemoglobin; MCHC, mean cell hemoglobin concentration; CHCM, cell hemoglobin concentration mean; CH, cellular hemoglobin content (mean of RBC cellular hemoglobin histogram); RDW, red cell distribution width; HDW, hemoglobin distribution width; PLT, platelet; MPV, mean platelet volume; Hyper, hyperchromia; Hypo, hypochromia; Macro, macrocytosis; Micro, microcytosis; MN, mononuclear cell; PMN, polymorphonuclear cell; cHb, calculated hemoglobin (CHCM×RBC×MCV÷1,000); NEUT, neutrophil; LYMPH, lymphocyte; MONO, monocyte; EOS, eosinophil; BASO, basophil; LUC, large unstained cell; LI, lobularity index; MPXI, myeloperoxidase index; WBCP, white blood cell count by peroxidase; RETIC-P, reticulocyte percent; RETIC-N, reticulocyte number; CHr, cellular hemoglobin mean of reticulocyte; CHm, cellular hemoglobin mean of mature RBC.

The MCHC, RBC ghosts, mHb-cHb, and MCHC-CHCM were finally selected for including in the scoring system for detecting IVH. The scores for the 4 parameters were defined as follows: score 0<34.0, 34.0 ≤score 1 ≤36.2, 36.3 ≤score 2 ≤38.4, and score 3 ≥38.5 for MCHC (g/dL); score 0<0.02, 0.02 ≤score 1<0.03, 0.03 ≤score 2<0.04, and score 3 ≥0.04 for RBC ghosts (1012/L); score 0<0.13, 0.13 ≤score 1 ≤0.38, 0.39 ≤score 2 ≤1.30, and score 3 ≥1.31 for mHb-cHb (g/dL); score 0<0.26; 0.26 ≤score 1 ≤0.95, 0.96 ≤score 2 ≤3.34, and score 3 ≥3.35 for MCHC-CHCM (g/dL). At a cutoff value of 3 for the hemolysis score (defined as the sum of all the scores of the 4 parameters), the IVH of aliquots B and C were detected as 64.9% and 91.9%, respectively (Table 4).
Table 4

Score ranges of hemolytic parameters between hemolyzed and non-hemolyzed specimens

Status of hemolysisScore sum N of the four hematologic parameters*
0123456789101112
Non-hemolyzed2012311
Hemolyzed (2 times)48163344121
Hemolyzed (5 times)212144222710

*Mean cell hemoglobin concentration (g/dL, score 0 <34.0, 34.0 ≤score 1 ≤36.2, 36.3 ≤score 2 ≤38.4, score 3 ≥38.5), red blood cell ghosts (1012/L, score 0 <0.02, 0.02 ≤score 1 <0.03, 0.03 ≤score 2 <0.04, score 3 ≥0.04), measured Hb-calculated Hb (g/dL, score 0 <0.13, 0.13 ≤score 1 ≤0.38, 0.39 ≤score 2 ≤1.30, score 3 ≥1.31), and mean cell hemoglobin concentration-cell hemoglobin concentration mean (g/dL, score 0 <0.26, 0.26 ≤score 1 0.95, 0.96 ≤score 2 ≤3.34, score 3 ≥3.35); †Scores of the four hematologic parameters was equally 1; ‡Aliquots B and C were mechanically hemolyzed by aspirating two and five times, respectively, through a 27-gauge needle.

This new scoring system was established in January 2013 at a tertiary-care university hospital in Wonju, Korea.

DISCUSSION

To accurately detect IVH with hematology analyzers, it is necessary to measure only the cell-free Hb in the blood specimens without adding RBC lysing solution. However, cell-associated and cell-free Hb are not distinguishable by colorimetric methods, which are used by hematology analyzers [5]. In the Advia hematology analyzer, Hb is evaluated by using two methods: (1) a standard cyanmethemoglobin colorimetric method and (2) flow cytometry. Flow cytometry is based on low- and high-angle laser light scatter and is used for measuring the volume of individual RBCs and Hb concentration [6]. The low- and high-angle light scatter signals are transformed into RBC volume and Hb concentration values, respectively. Flow cytometry enables the determination of the actual Hb mass within the RBC by multiplying the RBC volume by the Hb concentration on a cell-by-cell basis; therefore, this method can possibly be used for differentiating cell-associated and cell-free Hb. A novel analyte, designated as CHCM, has been introduced for the Advia hematology analyzer system. The CHCM indicates the average concentration of Hb within individual RBCs as measured by flow cytometry [6]. In comparison, the MCHC is a calculated value that indicates the average Hb concentration within RBCs based on an analysis of total colorimetric Hb in a hemolyzed specimen. Therefore, hemolysis or lipemia may result in a falsely elevated MCHC, whereas the CHCM is not affected. Among the hematologic parameters, the MCHC data range in hemolyzed specimens had the least overlap compared with non-hemolyzed specimens (Table 2). However, the mean CHCM in hemolyzed specimens was higher than that in non-hemolyzed specimens, although [B-A] and [C-A] showed a non-normal probability distribution and low correlation coefficients for HI values (Tables 1 and 3). During hematologic analysis, the CHCM and MCHC are automatically compared by the Advia software, and a Comparison Error MCHC/CHCM flag is generated if they differ by >1.9 g/dL [6]. Compared to this study (Table 2), a MCHC-CHCM cutoff value of 1.9 g/dL might be capable of detecting error conditions that could be affecting one or more of the three results (i.e., RBC, MCV, or Hb), used for calculating MCHC; however, this is associated with a low sensitivity for detecting IVH. It seemed that the MCHC-CHCM range was more useful than the MCHC-CHCM cutoff value for discriminating hemolyzed and non-hemolyzed specimens because the correlation coefficients of MCHC-CHCM and HI were high and increased in proportion with the increase in hemolysis (0.766 in [B-A] and 0.842 in [C-A]). In the Advia system, cHb values are calculated by using CHCM instead of MCHC to avoid lipemia interference [6]. In comparison to CHCM, cHb reflects the change effects of MCV and RBC by hemolysis, which might potentiate the hemolytic effect, because both MCV and RBC are decreased with hemolysis. The cHb was a suitable parameter for IVH because the mean cHb value in hemolyzed specimens was significantly lower than that in non-hemolyzed specimens, and the correlation coefficients of cHb and HI were high and proportionally decreased with hemolysis (-0.730 in [B-A] and -0.847 in [C-A]). However, 97.3% and 67.6% of cHb data in aliquots B and C, respectively, were overlapped with those in non-hemolyzed specimens (Table 2). Among the hematologic parameters, mHb-cHb showed the highest correlation coefficients with HI and the second lowest overlap between hemolyzed and non-hemolyzed specimens (Tables 1 and 2). RBC ghosts, one of the hematologic flags, are displayed on the PLT scatter cytogram of the Advia system. The PLT scatter cytogram is the graphical representation of two light-scatter measurements: (1) the high-angle light scatter plotted on the X-axis and (2) the low-angle light scatter plotted on the Y-axis. The low- and high-angle light scatter signals are transformed into volume and refractive index (n) values, respectively [6]. The RBC ghost morphology flag is generated, if the number of events in the RBC ghost area of the PLT scatter cytogram is>1011 cells/L. The events counted in the RBC ghost area of the PLT scatter cytogram have refractive indices <1.350. The sample-related causes of RBC ghost morphology flag are the presence of hemolysis, cryoglobulins, chylomicrons, pyropoikilocytosis, and lipemia [6, 7]. In the present study, the number of events in the RBC ghost area could be used as an informative marker of IVH, even though it is lower than the cutoff value of flag generation, regardless of the severity of hemolysis. This may be because the methods for measuring RBC ghosts is different from the detection method for Hb, and the overlap percentage of RBC ghost between aliquots A and C was as low as 37.8%. Finally, the four hematologic parameters and their scores are displayed on a workstation monitor for laboratory personnel, and the sum of scores is reported through a personal computer monitor to the medical staff. Our scoring system will provide an effective screening method for detecting IVH, although the associated sensitivity is not quite satisfactory. In addition, the scoring system will educate clinicians and nurses about the relationship between improper blood sampling and hematologic testing results. One limitation of our scoring system was that we did not evaluate the relationship between other preanalytic interferents, such as lipemia and icterus, and the four hematologic parameters. Additionally, the HI and LDH levels were not measured in the plasma of aliquot A. If any of the aliquot A sample had IVH, it could possibly influence the data analysis of hemolytic parameters. We expect that a more sensitive and precise scoring system for IVH, according to age, Hb concentration, and underlying hematologic disease, will be examined in future studies.
  4 in total

1.  Automated quantitation of hemoglobin-based blood substitutes in whole blood samples.

Authors:  J Kunicka; M Malin; D Zelmanovic; M Katzenberg; W Canfield; P Shapiro; N Mohandas
Journal:  Am J Clin Pathol       Date:  2001-12       Impact factor: 2.493

Review 2.  Hemolyzed specimens: a major challenge for emergency departments and clinical laboratories.

Authors:  Giuseppe Lippi; Mario Plebani; Salvatore Di Somma; Gianfranco Cervellin
Journal:  Crit Rev Clin Lab Sci       Date:  2011 May-Jun       Impact factor: 6.250

3.  Identification of spurious hemolysis in anticoagulated blood with Sysmex XE-2100 and Siemens Advia 2120.

Authors:  Giuseppe Lippi; Silvia Pipitone; Daniela Gennari; Massimo Franchini
Journal:  Clin Lab       Date:  2012       Impact factor: 1.138

4.  Development of an integrated reporting system for verifying hemolysis, icterus, and lipemia in clinical chemistry results.

Authors:  Dong Hoon Shin; Juwon Kim; Young Uh; Se Il Lee; Dong Min Seo; Kab Seung Kim; Jae Yun Jang; Man Hee Lee; Kwang Ro Yoon; Kap Jun Yoon
Journal:  Ann Lab Med       Date:  2014-06-19       Impact factor: 3.464

  4 in total
  1 in total

1.  ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats.

Authors:  Oliver A Garden; Linda Kidd; Angela M Mexas; Yu-Mei Chang; Unity Jeffery; Shauna L Blois; Jonathan E Fogle; Amy L MacNeill; George Lubas; Adam Birkenheuer; Simona Buoncompagni; Julien R S Dandrieux; Antonio Di Loria; Claire L Fellman; Barbara Glanemann; Robert Goggs; Jennifer L Granick; Dana N LeVine; Claire R Sharp; Saralyn Smith-Carr; James W Swann; Balazs Szladovits
Journal:  J Vet Intern Med       Date:  2019-02-26       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.